index - Epidemiology in dermatology and evaluation of therapeutics

DOCUMENTS

98

 

NOTICES

156

 

 

MOTS CLES

Azathioprine Anxiété Cardio-oncology Psoriasis Adolescent Bacterial Endocrine toxicity Angiotensin receptor blockers Auto-Diagnostic Alcohol Ethics Aging Biologic Cardiomyopathy Biosimilar Pharmaceuticals Cardiotoxicity Prostate cancer Autoimmunity Immunotherapy Dermatology Angiotensin-converting enzyme inhibitors Autoimmune diseases Anticancer drugs Epidemiology Etanercept Biomédicaments Bacterial rhinosinusitis Apremilast Stability Biological Therapy Biologics Biologic therapy Immune-related adverse events Antimicrobial Stewardship Anti-TNF Placebo Adalimumab Burden Biomarkers Network meta-analysis Meta-Analysis Infliximab Adverse side effects Pregnancy Arrhythmia Access to care Spondylitis Pharmaco-Épidémiologie Pharmacoepidemiology BTK protein ASDAS Albinism Anti-Bacterial Agents Atrial fibrillation Management Antibiotics COVID-19 Antimicrobial resistance Antibiotic misuse Cancer Anti-HCV Direct Acting Antivirals DAA Spondyloarthritis Atopic dermatitis Arthritis Ankylosing spondylitis Biologic drug Acute Myeloid Leukaemia AML Drug survival Antibiotic resistance Primary adrenal insufficiency Beta-lactam antibiotics Pharmacovigilance Accelerometer Biological therapy Antimicrobials Abus d'antibiotiques Apre-milast Systematic review Alitretinoin Glucocorticoids Antimicrobiens Auto-immune hepatitis Ankylosing Addiction Méta-Analyse Graft-versus-host disease ArtThese Psoriatic arthritis Vigibase® Treatment Axial spondyloarthritis Immune checkpoint inhibitors Sipuleucel-T Ustekinumab Sacroiliitis Drug reaction Anxiety Intensive care Quality of life Amyloidosis

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS